Reports Q3 revenue $19.91M, consensus $17.74M. “Our robust third-quarter performance and recent progress across both our interventional dry eye and glaucoma business segments demonstrates strong consistent commercial, clinical, market access, and operational execution as we build a leading interventional eye care company. Our Surgical Glaucoma revenue growth underscores the clinical significance of our OMNI technology in the glaucoma treatment paradigm and the effectiveness of our team, as we simultaneously streamlined the organization and drove efficiencies to reduce operating expenses,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences (SGHT).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Announces Key Management Changes
- Sight Sciences’ Latest Study on OMNI 3.0 System: A Potential Game-Changer for Glaucoma Treatment
- Sight Sciences’ Helix Surgical System Study: A Potential Game-Changer for Glaucoma and Cataract Treatment
- Sight Sciences price target raised to $7 from $5 at Lake Street
- Sight Sciences Gains Medicare Pricing for TearCare